May 14, 2019: Lack of Standardized Documentation Contributes to a Mix-up between Methadone and Buprenorphine-Naloxone
Opioid use disorder is one of the most challenging forms of addiction facing the Canadian healthcare system; almost 4000 Canadians lost their lives to an opioid-related overdose in 2017. The ability to treat opioid use disorder using opioid agonist treatment with methadone or, more recently, buprenorphine-naloxone (brand name Suboxone), has played an integral role in addressing Canada's Opioid Crisis. This bulletin shares a report of a medication incident in which nonstandardized documentation of opioid agonist treatment led to preventable harm. Read more ...
